Silvia Leoncini

List of Publications by Year
in descending order

77	3,316	159358	155451
papers	citations	30 h-index	55 g-index

78	78	78	3783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome, 2017, 5, 24.	4.9	668
2	Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetologica, 2013, 50, 489-495.	1.2	176
3	Systemic oxidative stress in classic Rett syndrome. Free Radical Biology and Medicine, 2009, 47, 440-448.	1.3	140
4	Ethanol-induced oxidative stress: basic knowledge. Genes and Nutrition, 2010, 5, 101-109.	1.2	133
5	Altered gut microbiota in Rett syndrome. Microbiome, 2016, 4, 41.	4.9	120
6	Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiology of Disease, 2014, 68, 66-77.	2.1	118
7	Plasma F2-isoprostanes are elevated in newborns and inversely correlated to gestational age. Free Radical Biology and Medicine, 2004, 37, 724-732.	1.3	103
8	The role of oxidative stress in Rett syndrome: an overview. Annals of the New York Academy of Sciences, 2012, 1259, 121-135.	1.8	95
9	F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. Journal of Lipid Research, 2011, 52, 2287-2297.	2.0	93
10	Partial rescue of Rett syndrome by Ï‰-3 polyunsaturated fatty acids (PUFAs) oil. Genes and Nutrition, 2012, 7, 447-458.	1.2	76
11	Free iron, total F₂â€isoprostanes and total F₄â€neuroprostanes in a model of neonatal hypoxicâ€“ischemic encephalopathy: neuroprotective effect of melatonin. Journal of Pineal Research, 2009, 46, 148-154.	3.4	71
12	F4-neuroprostanes mediate neurological severity in Rett syndrome. Clinica Chimica Acta, 2011, 412, 1399-1406.	0.5	68
13	Oxidative stress in Rett syndrome: Natural history, genotype, and variants. Redox Report, 2011, 16, 145-153.	1.4	64
14	Increased levels of 4HNE-protein plasma adducts in Rett syndrome. Clinical Biochemistry, 2011, 44, 368-371.	0.8	63
15	Genes Related to Mitochondrial Functions, Protein Degradation, and Chromatin Folding Are Differentially Expressed in Lymphomonocytes of Rett Syndrome Patients. Mediators of Inflammation, 2013, 2013, 1-18.	1.4	62
16	Cytokine Dysregulation inMECP2- andCDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, andÏ‰-3 PUFAs. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-18.	1.9	61
17	Subclinical Inflammatory Status in Rett Syndrome. Mediators of Inflammation, 2014, 2014, 1-13.	1.4	60
18	Morphological changes and oxidative damage in Rett Syndrome erythrocytes. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 511-520.	1.1	59

#	Article	IF	Citations
19	Scavenger receptor B1 postâ€translational modifications in Rett syndrome. FEBS Letters, 2013, 587, 2199-2204.	1.3	55
20	Revealing the Complexity of a Monogenic Disease: Rett Syndrome Exome Sequencing. PLoS ONE, 2013, 8, e56599.	1.1	54
21	Plasma Esterified F2-Isoprostanes and Oxidative Stress in Newborns: Role of Nonprotein-Bound Iron. Pediatric Research, 2008, 63, 287-291.	1.1	50
22	Iron Release in Erythrocytes and Plasma Non Protein-bound Iron in Hypoxic and Non Hypoxic Newborns. Free Radical Research, 2003, 37, 51-58.	1.5	47
23	MtDNA mutagenesis impairs elimination of mitochondria during erythroid maturation leading to enhanced erythrocyte destruction. Nature Communications, 2015, 6, 6494.	5.8	47
24	Redox Imbalance and Morphological Changes in Skin Fibroblasts in Typical Rett Syndrome. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-10.	1.9	44
25	Iron release, superoxide production and binding of autologous IgG to band 3 dimers in newborn and adult erythrocytes exposed to hypoxia and hypoxia-reoxygenation. Biochimica Et Biophysica Acta - General Subjects, 2004, 1672, 203-213.	1.1	43
26	Non-protein-bound iron and 4-hydroxynonenal protein adducts in classic autism. Brain and Development, 2013, 35, 146-154.	0.6	40
27	Subclinical myocardial dysfunction in Rett syndrome. European Heart Journal Cardiovascular Imaging, 2012, 13, 339-345.	0.5	37
28	Isoprostanes and 4-Hydroxy-2-nonenal: Markers or Mediators of Disease? Focus on Rett Syndrome as a Model of Autism Spectrum Disorder. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-10.	1.9	36
29	Erythrocyte Shape Abnormalities, Membrane Oxidative Damage, andÎ²-Actin Alterations: An Unrecognized Triad in Classical Autism. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	35
30	Expression and oxidative modifications of plasma proteins in autism spectrum disorders: Interplay between inflammatory response and lipid peroxidation. Proteomics - Clinical Applications, 2016, 10, 1103-1112.	0.8	33
31	F2-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie, 2013, 95, 86-90.	1.3	30
32	Relevance of 4-F4t-neuroprostane and 10-F4t-neuroprostane to neurological diseases. Free Radical Biology and Medicine, 2018, 115, 278-287.	1.3	30
33	Unrecognized Lung Disease in Classic Rett Syndrome. Chest, 2010, 138, 386-392.	0.4	28
34	Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: Effects of omega-3 polyunsaturated fatty acid supplementation. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 91, 183-193.	1.0	25
35	Rett syndrome: An autoimmune disease?. Autoimmunity Reviews, 2016, 15, 411-416.	2.5	25
36	MECP2 Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison with Rett Syndrome. PLoS ONE, 2016, 11, e0150101.	1.1	22

#	Article	IF	Citations
37	Pathology of perinatal brain damage: background and oxidative stress markers. Archives of Gynecology and Obstetrics, 2014, 290, 13-20.	0.8	21
38	Inflammatory Lung Disease in Rett Syndrome. Mediators of Inflammation, 2014, 2014, 1-15.	1.4	19
39	Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder. Free Radical Biology and Medicine, 2015, 86, 156-165.	1.3	19
40	Effects ofÏ‰-3 PUFAs Supplementation on Myocardial Function and Oxidative Stress Markers in Typical Rett Syndrome. Mediators of Inflammation, 2014, 2014, 1-8.	1.4	18
41	Immune Dysfunction in Rett Syndrome Patients Revealed by High Levels of Serum Anti-N(Glc) IgM Antibody Fraction. Journal of Immunology Research, 2014, 2014, 1-6.	0.9	18
42	Beta-Actin Deficiency with Oxidative Posttranslational Modifications in Rett Syndrome Erythrocytes: Insights into an Altered Cytoskeletal Organization. PLoS ONE, 2014, 9, e93181.	1.1	18
43	Persistent Unresolved Inflammation in the Mecp2-308 Female Mutated Mouse Model of Rett Syndrome. Mediators of Inflammation, 2017, 2017, 1-9.	1.4	17
44	Hypoxia affects the physiological behavior of rat cortical synaptosomes. Free Radical Biology and Medicine, 2007, 42, 1749-1756.	1.3	16
45	Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in diabetic patients. Free Radical Research, 2008, 42, 716-724.	1.5	16
46	Oxidative stress and autologous immunoglobulin G binding to band 3 dimers in newborn erythrocytes. Free Radical Biology and Medicine, 2006, 40, 907-915.	1.3	15
47	Increased non-protein bound iron in Down syndrome: contribution to lipid peroxidation and cognitive decline. Free Radical Research, 2016, 50, 1422-1431.	1.5	15
48	Proteomic analysis of the Rett syndrome experimental model mecp2Q63X mutant zebrafish. Journal of Proteomics, 2017, 154, 128-133.	1.2	15
49	Hypoxia-Induced Post-Translational Changes in Red Blood Cell Protein Map of Newborns. Pediatric Research, 2005, 58, 660-665.	1.1	14
50	Isoprostanoids in Clinical and Experimental Neurological Disease Models. Antioxidants, 2018, 7, 88.	2.2	14
51	Effects of 50 Hz electromagnetic fields on rat cortical synaptosomes. Toxicology and Industrial Health, 2009, 25, 249-252.	0.6	13
52	Effects ofÏ‰-3 Polyunsaturated Fatty Acids on Plasma Proteome in Rett Syndrome. Mediators of Inflammation, 2013, 2013, 1-9.	1.4	12
53	Red blood cells in Rett syndrome: oxidative stress, morphological changes and altered membrane organization. Biological Chemistry, 2015, 396, 1233-1240.	1.2	12
54	Increased isoprostanoid levels in brain from murine model of Krabbe disease â€“ Relevance of isoprostanes, dihomo-isoprostanes and neuroprostanes to disease severity. Free Radical Biology and Medicine, 2019, 139, 46-54.	1.3	12

#	Article	IF	Citations
55	The Physiological Behaviour of IMR-32 Neuroblastoma Cells is Affected by a 12-h Hypoxia/24-h Reoxygenation Period. Neurochemical Research, 2010, 35, 1691-1699.	1.6	11
56	A Plasma Proteomic Approach in Rett Syndrome: Classical versus Preserved Speech Variant. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	11
57	Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation. Inflammation Research, 2017, 66, 269-280.	1.6	11
58	Defective proteasome biogenesis into skin fibroblasts isolated from Rett syndrome subjects with MeCP2 non-sense mutations. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165793.	1.8	11
59	Intestinal Candida parapsilosis isolates from Rett syndrome subjects bear potential virulent traits and capacity to persist within the host. BMC Gastroenterology, 2018, 18, 57.	0.8	9
60	Brain protein changes in Mecp2 mouse mutant models: Effects on disease progression of Mecp2 brain specific gene reactivation. Journal of Proteomics, 2020, 210, 103537.	1.2	9
61	F2-Isoprostanes in soft oral tissues and degree of oral disability after mandibular third molar surgery. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 114, 344-349.	0.2	8
62	Protective role of mirtazapine in adult female Mecp2+/â˜’ mice and patients with Rett syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 26.	1.5	8
63	Abnormal N-glycosylation pattern for brain nucleotide pyrophosphatase-5 (NPP-5) in Mecp2-mutant murine models of Rett syndrome. Neuroscience Research, 2016, 105, 28-34.	1.0	7
64	Breathing Abnormalities During Sleep and Wakefulness in Rett Syndrome: Clinical Relevance and Paradoxical Relationship With Circulating Pro-oxidant Markers. Frontiers in Neurology, 2022, 13, 833239.	1.1	7
65	The role of preoperative oxidative stress and mandibular third molar postoperative outcome. International Journal of Oral and Maxillofacial Surgery, 2013, 42, 1499-1500.	0.7	5
66	Scavenger Receptor B1 oxidative post-translational modifications are responsible for its loss in Rett syndrome. Free Radical Biology and Medicine, 2014, 75, S10-S11.	1.3	5
67	Erythrocyte Cytoskeletal-plasma Membrane Protein Network in Rett Syndrome: Effects of .-3 Polyunsaturated Fatty Acids. Current Proteomics, 2016, 12, 217-226.	0.1	5
68	Oxidative stress: a hallmark of Rett syndrome. Future Neurology, 2015, 10, 179-182.	0.9	4
69	The Effects of Hypoxia/Reoxygenation on the Physiological Behaviour of U373-Mg Astrocytes. Neurochemical Research, 2010, 35, 42-49.	1.6	3
70	Fatty Acids and Autism Spectrum Disorders: The Rett Syndrome Conundrum. Food and Nutrition Sciences (Print), 2013, 04, 71-75.	0.2	3
71	Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease. Life, 2022, 12, 146.	1.1	2
72	Circulating 4-F4t-Neuroprostane and 10-F4t-Neuroprostane Are Related to MECP2 Gene Mutation and Natural History in Rett Syndrome. International Journal of Molecular Sciences, 2021, 22, 4240.	1.8	1

#	Article	IF	Citations
73	4HNE Protein Adducts in Autistic Spectrum Disorders: Rett Syndrome and Autism. , 2014, , 2667-2687.		1
74	MEASLES MUMPS AND RUBELLA VACCINATION AND AUTISM: MISPERCEPTION/MISCOMMUNICATION VS. SCIENTIFIC EVIDENCE. RESULTS OF A BLINDED ANONYMOUS ITALIAN SURVEY. Journal of the Siena Academy of Sciences, 2017, 8, .	0.0	0
75	Iron and Erythrocytes: Physiological and Pathophysiological Aspects. , 2008, , 167-181.		0
76	Biomarkers of Lipid Oxidative Damage in Rett Syndrome. , 2014, , 2617-2632.		0
77	Neuroprostanes and Neurological Severity in Rett Syndrome. , 2014, , 2633-2645.		0